Trimethoprim-sulfamethoxazole is one of 144 small molecule programs targeting Kidney. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
107 competitors in Cystic Fibrosis
Ibsrela
Zyvox
Avelox
HSK31858
Trimethoprim-sulfamethoxazole
Myambutol
Tygacil
Sirturo
ELX/TEZ/IVA
Trikafta
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources